Venture Leaders Biotech 2026: 10 innovative biotech startups selected for the Boston roadshow

Ten startups have been selected for the 2026 Venture Leaders Biotech program, which will take them to Boston from May 31st to June 5th as part of the Swiss National Startup Team. During their roadshow, the entrepreneurs will connect with international investors and industry leaders, acquiring expertise to help scale their ventures internationally. Venture Leaders Biotech is organized by Venturelab and supported by EPF Lausanne, ETH Zurich, University of Basel, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.

Since 2006, Venturelab has been selecting the Swiss National Startup Team. Through its Venture Leaders roadshows, entrepreneurs engage with top experts, investors, and potential customers in leading global tech hubs, including Silicon Valley, Boston, Asia, Barcelona, London, and Munich.

After reviewing over 70 applications, a jury of experts and investors selected ten startups for the 2026 Venture Leaders Biotech roadshow in Boston. The program provides entrepreneurs the chance to accelerate their US expansion, connect with industry leaders, and gain insights through investor pitch sessions and targeted workshops.

The ten selected startups represent an array of fields, such as AI-driven drug design, vaccines, peptide therapeutics, bioreactors, CAR-T therapy, in-vivo gene editing, enzyme delivery, RNA-targeted therapies, proteomics, and organoid automation.

"Getting ready for this roadshow for the 21st year is a great reflection of the quality of innovation of the new startups involved," said Jordi Montserrat, Managing Partner of Venturelab. "I’m looking forward to being part of this new edition and assisting the team with their fundraising and international expansion."

The 10 startups will follow in the footsteps of high-flying former team members such as Araris Biotech (recently announced its acquisition for USD 1.1 billion), Covagen (acquired by Johnson & Johnson), Versantis (acquired by Genfit), AMAL Therapeutics (acquired by Boehringer Ingelheim), NBE-Therapeutics (acquired by Boehringer Ingelheim), Alentis (USD 105 million funding round in 2023), and BioVersys (recent IPO on the SIX Swiss Exchange).

The team will kick off the program pitching at the Swiss Biotech Days in Basel on May 4, 2026 (17:45-18:30 in room Singapore). Follow the Venture Leaders Biotech roadshow on social media using the hashtag #VLeadersBiotech or on www.venture-leaders.ch/venture-leaders-biotech from May 31st to June 5th, 2026. The Venture Leaders Biotech is organized by Venturelab and supported by EPFL, ETH Zurich, University of Basel, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.

Meet the Venture Leaders Biotech 2026: